Patients with ANCA-associated vasculitis (AAV) have fewer adverse events and better quality of life when treated with avacopan over…
Articles by Iqra Mumal, MSc
A faulty immune system component in patients with active ANCA-associated vasculitis (AAV) is not equipped to stop ANCA-induced neutrophil activation,…
Ear, nose, and throat symptoms in patients with granulomatosis with polyangiitis (GPA) are associated with better overall survival and…
Low daily doses of oral prednisone — 2.5 mg/day or less — during long-term remission maintenance therapy was associated with a…
A shorter glucocorticoid treatment course, given in combination with Rituxan (rituximab), may be beneficial for some patients with ANCA-associated vasculitis,…
Patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) exhibit abnormalities in heart function near the time of diagnosis, a…
The addition of azathioprine, an immunosuppressant, to a glucocorticoid treatment regimen does not improve remission rates for patients with non-severe…
Patients are more likely to develop anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) that affects their kidneys in the winter months,…
The thyroid medication propylthiouracil (PTU) can sometimes cause antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but a new study shows…
Rituxan (rituximab) is a safe and effective treatment for patients with anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) and should be…